As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As Ranbaxy struggles to deal with U.S. FDA allegations of GMP violations and data falsification at its two Indian manufacturing sites - Paonta Sahib and Dewas - clouds are gathering over its ability to launch a generic equivalent of the planet's largest drug brand Lipitor (atorvastatin) in the United States, about a year from now
You may also be interested in...
Will Ranbaxy Tie Up With Teva To Launch Generic Lipitor?
MUMBAI - Breaking a long silence, Ranbaxy Laboratories Ltd. Managing Director Arun Sawhney told investors last week that he is "very optimistic" about keeping the U.S. launch date of generic versions of Lipitor (atorvastatin), the largest pharmaceutical brand
Will Ranbaxy Tie Up With Teva To Launch Generic Lipitor?
MUMBAI - Breaking a long silence, Ranbaxy Laboratories Ltd. Managing Director Arun Sawhney told investors last week that he is "very optimistic" about keeping the U.S. launch date of generic versions of Lipitor (atorvastatin), the largest pharmaceutical brand